Apeiron Investment Group, angel investor Peter Thiel, and Catalio Capital Management have led a $125m series-C round for Germany-based psychedelic and non-psychedelic mental health therapy compounds developer Atai Life Sciences.
Apeiron Investment Group, angel investor Peter Thiel, and Catalio Capital Management have led a $125m series-C round for Germany-based psychedelic and non-psychedelic mental health therapy compounds developer Atai Life Sciences.